

Catalog Number: CM04753

### 产品信息

**Catalog Number:**  
CM04753

**CAS号:**  
304456-62-0


**分子式:**  
C<sub>12</sub>H<sub>9</sub>BrN<sub>2</sub>OS

**主要靶点:**  
c-Myc|NF-κB|Others

**主要通路:**  
其他|NF-κB信号通路|细胞周期

**分子量:**  
309.18

**溶解度:**  
DMSO:62 mg/mL (200.53  
mM),Ethanol:4 mg/mL (12.94 mM)



### 靶点活性

IMP1 c-Myc mRNA interaction: 5 μM (IC<sub>50</sub>)

### 体外活性

In cells, BTYNB downregulates several mRNA transcripts regulated by IMP1. BTYNB destabilizes c-Myc mRNA, resulting in downregulation of c-Myc mRNA and protein. BTYNB downregulates β-TrCP1 mRNA and reduces activation of nuclear transcriptional factors-kappa B (NF-κB). The oncogenic translation regulator, eEF2, emerged as a new IMP1 target mRNA, enabling BTYNB to inhibit tumor cell protein synthesis. BTYNB potently inhibited proliferation of IMP1-containing ovarian cancer and melanoma cells with no effect in IMP1-negative cells. Overexpression of IMP1 reversed BTYNB inhibition of cell proliferation. BTYNB completely blocked anchorage-independent growth of melanoma and ovarian cancer cells in colony formation assays. With its ability to target c-Myc and to inhibit proliferation of difficult-to-target melanomas and ovarian cancer cells, and with its unique mode of action, BTYNB is a promising small molecule for further therapeutic evaluation and mechanistic studies[1].

### 描述

BTYNB (MDK6620) is an inhibitor of the oncofetal mRNA-binding protein IMP1 (IC<sub>50</sub> = 5 μM for IMP1 binding to c-Myc mRNA). MDK6620 downregulates β-TrCP1 mRNA and reduces activation of nuclear transcriptional factors-kappa B (NF-κB). It disrupts this enhancer function by impairing IGF2 mRNA-binding protein 1 (IGF2BP1)-RNA association

### 储存

Powder: -20°C for 3 years | In solvent: -80°C for 2 years